6/4/2014 1:00:00 AM
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
5/22/2014 1:00:00 AM
KineMed Inc. today announced the appointment of Patrick James Doyle as Executive Vice President & Chief Business Officer. Doyle joins KineMed from PPD where he most recently served as Vice President, Strategic Partnerships.
5/19/2014 1:00:00 AM
EMERYVILLE, CA, May 19, 2014, – KineMed, Inc. and CHDI Foundation, Inc. announced today an extension of their collaboration that uses KineMed’s translational biomarker platform to characterize and track the pathogenesis of Huntington’s disease (HD) and evaluate potentially therapeutic interventions.
Marc Hellerstein, M.D., Ph.D., President and Chief Scientific Officer
talks about the power of Proteome Dynamics at the Personalized Medicine World Conference